Stingray Bio is a new UK biotech launched in 2021 to exploit years of leading academic research linking LMTK3 to essential disease biology in breast and other cancers. Our discovery-stage programmes are progressing specific small-molecule inhibitors of LMTK3 kinase towards clinical application. Leveraging our founding team’s extensive knowledge in the structural biology, cellular and cancer pharmacology of LMTK3, we anticipate our novel cancer agents targeting this unexploited kinase will find application in diverse cancer types and therapeutic applications.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.stingraybio.com
- Keywords
- Neuractive.
Stingray Bio Ltd Questions
Stingray Bio Ltd's website is http://www.stingraybio.com
Stingray Bio Ltd's LinkedIn profile is https://www.linkedin.com/company/stingray-bio-ltd
Stingray Bio Ltd's industry is
Biotechnology Research
Stingray Bio Ltd's top competitors are
Neurometry,
Neuractive,
Alevin Therapeutics Ltd,
Neurocentrx Pharma Ltd.,
Caritas Bioscience,
Pharosai,
Neo Kuma Ventures,
Alusid Ltd,
Bioventure Works,
Neophore Ltd.
Stingray Bio Ltd's categories are Biotechnology Research
Stingray Bio Ltd's founding year is 2021
